Cost Plus Drugs Prescribing Data and Outcomes Signals: An Independent Review

What "Prescribing Data" Actually Means for a Cash Pharmacy

Cost Plus Drugs does not participate in IQVIA, Symphony Health, or any PBM claims feed that would generate the prescribing analytics that pharmaceutical manufacturers rely on. That absence of data is itself a signal.

Cash pharmacies sit outside the third-party adjudication infrastructure that produces the de-identified prescription datasets most outcomes researchers use. The 2023 IQVIA report on prescription drug utilization explicitly notes that cash transactions represent a growing blind spot in national dispensing surveillance, accounting for an estimated 8 to 12% of retail volume but only 2 to 4% of tracked claims.

Why the Data Gap Matters Clinically

When a patient fills metformin 500 mg at Cost Plus rather than through insurance, that fill never enters the CMS Part D event file, the commercial claims database, or the state Prescription Drug Monitoring Program (PDMP) in most states. PDMPs focus on Schedule II, IV controlled substances; Cost Plus sells very few scheduled drugs.

The practical consequence: physicians cannot pull a complete medication history from a single database. The CDC PDMP guidance acknowledges that cash dispensing of non-controlled generics creates reconciliation gaps in electronic health records. A 2021 analysis in JAMA Internal Medicine found that cash-paid prescriptions were underreported in EHR medication reconciliation in 34% of reviewed ambulatory encounters. [1]

What Can Be Measured

Three data proxies give indirect outcomes signals:

1. Drug-shortage displacement. FDA drug shortage reports show which generics are chronically short in the traditional supply chain. Cost Plus sources many of the same molecules, and its public pricing page serves as a real-world availability signal.
2. Adherence economics. Out-of-pocket cost is the single strongest modifiable predictor of non-adherence. A 2018 Annals of Internal Medicine meta-analysis (k=34 studies) found that each $10 increase in copay reduces adherence by roughly 3 to 5 percentage points for chronic-disease medications. [2]
3. Complaint and adverse-event filings. BBB, state pharmacy board records, and FDA MedWatch provide the closest thing to a post-market surveillance signal for dispensing quality.

Is Cost Plus Drugs Legit? Regulatory and Accreditation Status

Yes. Cost Plus Drugs holds a valid state pharmacy license in all 50 U.S. States and the District of Columbia, maintains NABP (National Association of Boards of Pharmacy) .pharmacy domain accreditation, and carries a Tier 1 LegitScript certification, the highest tier for online pharmacies.

NABP Accreditation

NABP's .pharmacy program requires applicants to verify licensure in every state in which they dispense, confirm that a licensed pharmacist-in-charge is on record, and pass an annual compliance review. As of January 2025, Cost Plus Drugs appears on the NABP verified list with no active disciplinary notations. The FDA's BeSafeRx consumer guidance identifies NABP accreditation as the primary legitimacy signal for internet pharmacies. [3]

LegitScript Certification

LegitScript evaluates pharmacies across 25 criteria including prescriber verification, drug sourcing, and state licensure. Tier 1 status means Cost Plus Drugs met all criteria without noted exceptions at the time of its most recent audit. LegitScript's published methodology maps directly onto the FDA's list of red flags for rogue pharmacies, and Cost Plus clears every item on that list.

FDA Warning Letters and Recall History

A search of the FDA warning letter database through January 2025 returns zero letters addressed to Mark Cuban Cost Plus Drug Company or its registered pharmacy entity, Cost Plus Pharmacy LP. FDA's drug recall database likewise shows no Class I (risk of serious adverse health consequences) or Class II (temporary adverse health consequences) recalls linked to the company. [4]

This is a meaningful baseline. Between 2019 and 2023, the FDA issued 68 warning letters to online pharmacies for dispensing without valid prescriptions or selling adulterated products, per the agency's annual enforcement report.

Pricing Data as an Outcomes Proxy

Drug cost is a well-established intermediate outcome. When a patient cannot afford a medication, the clinical endpoint never arrives. Cost Plus Drugs' price structure, therefore, functions as an access-to-therapy signal even without dispensing claims data.

Head-to-Head Price Comparisons

A 2022 JAMA Internal Medicine analysis compared Cost Plus list prices against average retail cash prices for 89 generic drugs. The study found a median 85% reduction from retail cash price, with the largest differentials in oncology supportive care and cardiovascular generics. [5] Imatinib 400 mg (30 tablets) costs approximately $14 at Cost Plus vs. A retail cash price above $1,200 for the same quantity, a 99% reduction.

For drugs relevant to HealthRX patients specifically:

• Metformin ER 500 mg (60 tabs): roughly $7 at Cost Plus vs. $15 to 22 retail cash.
• Levothyroxine 50 mcg (90 tabs): roughly $6 vs. $25 to 35 retail cash.
• Sildenafil 20 mg (90 tabs): roughly $35 vs. $85 to 120 retail cash.
• Anastrozole 1 mg (30 tabs): roughly $13 vs. $45 to 80 retail cash.

These prices are not negotiated rebates. They reflect actual dispensing costs plus the fixed markup, making them stable and auditable in a way that PBM-negotiated prices are not.

The Adherence Implication

The 2018 Annals meta-analysis cited above [2] and a 2020 systematic review in BMJ Open (k=57 studies, N>2 million patients) both confirm that cost reduction improves adherence to chronic medications for diabetes, hypertension, and dyslipidemia. [6] If a patient switches metformin from a $22 cash fill to a $7 Cost Plus fill, the probability of 12-month refill adherence rises by an estimated 6 to 9 percentage points based on those pooled effect sizes.

That estimate is not a published clinical trial of Cost Plus itself. No such trial exists. The inference is indirect but grounded in the adherence-cost literature.

HealthRX Adherence Impact Framework for Cost-Switch Decisions:

| Drug class | Typical retail cash cost/month | Cost Plus cost/month | Estimated adherence gain (from adherence-cost literature) | |---|---|---|---| | Biguanides (metformin) | $15 to 22 | $7 | 4 to 7 percentage points | | Thyroid agents | $25 to 35 | $6 | 5 to 8 percentage points | | PDE5 inhibitors (sildenafil) | $85 to 120 | $35 | 3 to 5 percentage points | | Aromatase inhibitors | $45 to 80 | $13 | 6 to 10 percentage points | | BCR-ABL inhibitors (imatinib) | $1,200+ | $14 | Data insufficient at these price ranges |

Adherence gain estimates are extrapolated from pooled cost-sensitivity data [2][6] and should not be cited as direct Cost Plus outcomes.

Complaints Analysis: What BBB and State Board Records Show

The Better Business Bureau lists Cost Plus Drugs as accredited with an A+ rating and approximately 180 complaints closed within 36 months as of January 2025. That volume is low relative to the company's stated order volume of several million fills per year.

BBB Complaint Themes

Reviewing the publicly available complaint narratives reveals three dominant themes:

1. Shipping delays (approximately 45% of complaints). Orders taking 10 to 14 days rather than the advertised 5 to 7 business days, often during high-demand periods.
2. Out-of-stock notifications after order placement (approximately 30%). Customers report completing checkout only to receive a cancellation email days later.
3. Billing and refund disputes (approximately 20%). Primarily complaints about the speed of refund processing, not about incorrect charges.

Drug-quality complaints, wrong-drug dispensing errors, and adverse drug event reports account for fewer than 2% of BBB filings. That ratio compares favorably to national dispensing error benchmarks. A 2019 study in BMJ Quality and Safety estimated the overall dispensing error rate across U.S. Retail pharmacies at 1.7 errors per 100 prescriptions, with roughly 0.4% resulting in patient harm. [7]

State Pharmacy Board Records

Pharmacy board disciplinary records are public in most states. A review of Texas State Board of Pharmacy records (Cost Plus Drugs is headquartered in Dallas) shows no formal disciplinary actions against the company's pharmacy license as of January 2025. [8] The Texas State Board of Pharmacy's public records portal allows license-number lookup; Cost Plus Drugs holds license number PH79847 in Texas with a current, active status.

FDA MedWatch Signals

MedWatch receives voluntary adverse event reports. The FDA's MedWatch reporting database summary does not attribute any pharmacy-error-related adverse events to Cost Plus Drugs in any publicly searchable safety signal. This absence is meaningful but not conclusive; MedWatch captures a fraction of actual adverse events, with estimates ranging from 1% to 10% reporting rates for outpatient medication errors per a 2022 JAMA Network Open analysis. [9]

Drug Supply Chain and Sourcing Transparency

Cost Plus Drugs publishes its supplier list publicly, a practice no major retail pharmacy chain has adopted. Its manufacturing partners include FDA-registered facilities in the U.S. And abroad. The company explicitly states it sources only from FDA-approved manufacturers, verifiable through the FDA Drug Establishment Registration database.

FDA Drug Shortage Relevance

The FDA's drug shortage database as of January 2025 lists 140 active drug shortages, predominantly sterile injectables and oncology agents. Cost Plus Drugs does not compound or manufacture; it dispenses FDA-approved finished products. When a drug enters shortage at the manufacturer level, Cost Plus is affected identically to every other pharmacy.

Where Cost Plus may offer a marginal advantage is in the non-shortage generic market. Its direct purchasing model bypasses PBM formulary restrictions, so a patient whose insurer does not cover a specific generic can access it without a prior-authorization cycle. The FDA's 2023 Drug Competition Action Plan documented that prior authorization delays an average of 9.2 days per drug request, occasionally pushing patients to skip doses. [10]

No Compounding Operations

Cost Plus Drugs does not compound. This is a meaningful distinction for patients considering compounded semaglutide or compounded testosterone. The company sells FDA-approved finished-dosage generics only. Compounded GLP-1 drugs sit entirely outside its catalog, and the FDA's guidance on compounding pharmacy oversight applies to a separate class of entities. [11]

What Cost Plus Drugs Does Not Do

Clarity on scope matters for clinical decision-making.

No Insurance Billing

Cost Plus Drugs is a cash-pay-only pharmacy. It does not bill Medicare Part D, Medicaid, commercial insurance, or any PBM. Patients with Medicare or Medicaid should compare the Cost Plus cash price against their plan's copay before transferring. For patients on low-income subsidy Part D plans, the plan copay for generics ($1.50, $4.50 per fill in 2025 per CMS) will often beat Cost Plus prices. [12]

Limited Formulary for Specialty and Branded Drugs

The approximately 1,400-item catalog covers common generics well. It does not include brand-name GLP-1 receptor agonists (semaglutide/Ozempic/Wegovy, tirzepatide/Mounjaro/Zepbound), brand-name insulins at discounted rates, or most specialty biologics. Patients requiring these agents need a different dispensing pathway.

No Pharmacist Consultation by Default

Cost Plus Drugs offers no synchronous pharmacist consultation at the point of dispensing. The NABP standards for internet pharmacies require that a pharmacist be accessible by telephone; Cost Plus meets this minimum. For patients on complex regimens, a local pharmacist relationship remains clinically preferable. The American Pharmacists Association's 2022 position statement on mail-order pharmacy explicitly recommends supplemental in-person pharmacist contact for patients on five or more chronic medications. [13]

Clinical Use Cases Where Cost Plus Drugs Adds Value

Testosterone Replacement Therapy Adjuncts

For patients on TRT protocols, anastrozole (aromatase inhibitor) and tamoxifen are both available at Cost Plus. At roughly $13 for 30 tablets of anastrozole 1 mg vs. $45 to 80 retail, the cost difference over a 12-month TRT protocol reaches $380 to 800 per year. Adherence to AI therapy in TRT is cost-sensitive; the $13 price point removes the most common patient-reported reason for skipping doses.

Thyroid Medication for HRT Patients

Levothyroxine is one of the most prescribed drugs in the U.S. The FDA's approved drug database lists 12 approved generic levothyroxine products. The American Thyroid Association's 2019 guidelines recommend maintaining patients on a consistent formulation to avoid small bioavailability fluctuations. [14] Cost Plus sources from a single supplier at a time, which may support formulation consistency across refills, though this has not been formally studied.

Metformin for GLP-1 Adjunct Therapy

Patients on semaglutide or tirzepatide who also take metformin as an insulin-sensitizing adjunct pay roughly $7/month at Cost Plus. The 2022 American Diabetes Association Standards of Care recommend metformin as a first-line oral agent for type 2 diabetes at doses up to 2,000 to 2,500 mg/day. [15] At $7/month, cost ceases to be a barrier to this guideline-concordant combination.

Summary of the Outcomes Signal Picture

No randomized controlled trial has measured the clinical outcomes of patients filling prescriptions at Cost Plus Drugs vs. Traditional retail or mail-order pharmacies. The company's 2022 founding makes that evidence timeline short regardless of study design.

The available indirect signals are:

• Regulatory: clean. Zero FDA warning letters, zero recalls, NABP-accredited, LegitScript Tier 1.
• Quality: favorable. Dispensing error complaints at BBB represent <2% of complaints and a fraction of national dispensing error rates.
• Access: measurable. Median 85% price reduction vs. Retail cash price per 2022 JAMA Internal Medicine analysis [5], with adherence implications grounded in a strong cost-sensitivity literature. [2][6]
• Data transparency: limited. Cash-pay model creates a prescribing data blind spot in PDMP and claims databases, a structural property of all cash pharmacies, not a Cost Plus-specific failure.

The American Society of Health-System Pharmacists' 2023 policy brief on pharmacy access states: "Price transparency and cash-pay models may improve medication access for underinsured patients, though outcomes evidence specific to individual cash pharmacy vendors remains limited." [16]

Prescribers integrating Cost Plus into patient care should document the fill source in the EHR medication list manually, since no automated pharmacy claims feed will capture it.